TopiVert Pharma Limited
http://www.topivert.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From TopiVert Pharma Limited
Chinese Biotech Fundraising Pace Slows Down In September
The $68m raised by Createrna in a series A round was the biggest biotech financing deal backed by venture capital firms in China in September. Two other noteworthy fundings in the country involved cell therapy specialist Qihan Biotech and therapeutic cancer vaccine maker Neoantigen Therapeutics.
China's Ongoing 'COVID Zero' Policies To Prompt More Domestic Deals?
China biotechs appear increasingly interested in partnering with domestic counterparts amid signs the Chinese government's restrictive "COVID Zero" policies are likely to stay until well into 2023.
HanAll Advancing Novel Dry Eye Contender Despite Mixed Top-Line
HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.
Kala Needs Big STRIDE To Get Dry Eye Drug OK
The US FDA has issued a complete response letter for KPI-121 but Kala hopes to resubmit the drug during the first half of next year backed by data from the ongoing STRIDE 3 study.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Drug Delivery
- Topical Delivery
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice